Enlivex CEO outlines roadmap after knee arthritis trial results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/1/2026

1. SPY
2. MDT
3. AAPL
4. SPGI
5. USO
6. DELL
7. ENOV
8. AON
9. NIO
10. A

Go back to Enlivex CEO outlines roadmap after knee arthritis trial results
Enliven Marketing Technologies Corporation (NASDAQ: ENLV) Delayed: 1.28 --0 (-0%)
Previous Close $1.28    52 Week High $0.94 
Open $1.27    52 Week Low $0.47 
Day High $1.31    P/E N/A 
Day Low $1.20    EPS $-0.11 
Volume 343,342